Incannex Healthcare Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its oral fixed-dose combination product candidate, IHL-42X, for the treatment of obstructive sleep apnea (OSA). The designation was based on promising results from three clinical trials, including a Phase 2 study that showed significant reductions in Apnea-Hypopnea Index and strong patient-reported outcomes. Fast Track status enables Incannex to benefit from more frequent interactions with the FDA, eligibility for rolling review, and potential access to Accelerated Approval and Priority Review, subject to meeting relevant criteria. No other organizations were mentioned as recipients of this grant or regulatory designation.